Biostem Technologies Inc. (BSEM)
OTC PINK OTC PINK Primary 
BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., October 30, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies, Inc. (BSEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
BioStem Technologies, Inc. (OTCPK:BSEM) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 3:20 PM EDT Company Participants Jason Matuszewski - CEO, President, Secretary & Chairman Conference Call Participants Denis Kelleher Presentation Denis Kelleher Let's kick off. I'm Denis Kelleher, Vice President of Morgan Stanley.
BioStem Showcasing its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Fall Meeting
Company co-exhibiting with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three scientific posters feature BioStem's proprietary allograft portfolio POMPANO BEACH, Fla., Sept. 05, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer
POMPANO BEACH, FL, August 21, 2025 – PRISM MediaWire – BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, discloses an insider purchase of common stock from Jason Matuszewski, Chairman and Chief Executive Officer of BioStem Technologies. Mr.
BioStem Technologies, Inc. (BSEM) Q2 2025 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Adam Holdsworth - Corporate Participant Brandon Poe - Corporate Participant Jason V. Matuszewski - CEO, President, Secretary & Chairman Michael A.
BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results
POMPANO BEACH, FL, August 14, 2025 – PRISM MediaWire – BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today reported preliminary financial results for the second quarter ended June 30, 2025.
BioStem Technologies Appoints Brandon Poe as Chief Financial Officer
Seasoned healthcare CFO with senior experience in capital markets and financial operations across private and publicly traded companies to lead BioStem's financial team POMPANO BEACH, FL, August 14, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., July 29, 2025 – PRISM MediaWire – BioStem Technologies Inc.
BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes
The Company welcomes CMS' efforts to reform skin substitute payment policy and will continue to engage with CMS and other stakeholders to optimize the proposed changes POMPANO BEACH, Fla., July 17, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies to Present at the Advanced Wound Care Summit in Boston on July 15, 2025, at 2:00 PM ET
Jason Matuszewski, Chairman and CEO, to present BioStem's current position in the chronic wound care market and key opportunities for growth POMPANO BEACH, Fla., July 10, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers
Head-to-head study comparing BioREtain®– processed Amnion Chorion (BR-AC) allograft to standard of care initiated in Q4 2024 to demonstrate healing superiority Topline results and full data analysis expected in Q4 2025 Audio Overview – Listened: POMPANO BEACH, Fla., June 23, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
Ernst & Young LLP (EY US) Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award Winner
Award celebrates bold leaders shaping the future through the world's most ground-breaking companies POMPANO BEACH, Fla., June 17, 2025 – PRISM MediaWire – Ernst & Young LLP (EY US) announced that Jason Matuszewski, CEO and Chairman of the Board of BioStem Technologies (OTC: BSEM), was named an Entrepreneur Of The Year 2025 Florida Award winner.
